Clinical trials: Ovary Disease
Ovarian Cancer
The Registry of Genetic Alterations of Taiwan Ovarian Cancer
Despite recent progress in chemotherapy and targeted therapy for ovarian cancer, the 5-year survival rate remains around 40% because of rapid development of treatment resistance and recurrence.
- Trial name
- NCT06127446
- Where
- 8 sites in Taiwan
- Volunteers
- 300 people
- Sponsor
- National Health Research Institutes, Taiwan
Ovarian Cancer
Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer
The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer.
- Trial name
- NCT00431054
- Testing
- Perifosine, Docetaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Sterility, Infertility
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
This is a prospective comparative randomized controlled study investigating the effect of Myo-Inositol-based co-treatment on oocyte quality measures in women with PCOS.
- Trial name
- NCT03177122
- Testing
- Myo-inositol
- Where
- Lebanon
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
PCOS, Polycystic Ovary Syndrome
Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome with a variety of metabolic and endocrine abnormalities and clinical symptoms.
- Trial name
- NCT01511822
- Testing
- Drospirenone Ethinyl estradiol, Drospirenone Ethinyl estradiol Myo-inositol
- Where
- Italy
- Sponsor
- AGUNCO Obstetrics and Gynecology Centre
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Metabolic Syndrome, Polycystic Ovary Syndrome
Combined Oral Contraceptive Pill and Resistance Starch
This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves…
- Trial name
- COR-PCOS (NCT06852365)
- Testing
- wheat dextrin, Oral Contraceptives, Low-Dose, Maltodextrin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania
Ovarian Cancer, Ascites
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients.
- Trial name
- iMETABO (NCT05025878)
- Testing
- [U-13C]Glucose
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Neoplasm
Phase II CT-2103/Carboplatin in Ovarian Cancer
The purpose of this study is to evaluate the safety and efficacy of CT-2103 (poly(L)glutamate-paclitaxel) in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer.
- Trial name
- NCT00069901
- Testing
- CT-2103 (poly(L)glutamate-paclitaxel), carboplatin
- Where
- 17 sites in United States
- Volunteers
- 82 people
- Sponsor
- CTI BioPharma
Ovarian Carcinoma
REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression
The objective of this randomized phase II is to evaluate the benefit of regorafenib for ovarian patients who reported a confirmed elevated CA-125 level under surveillance or bevacizumab, compared with tamoxifen.
- Trial name
- REGOVAR (NCT02584465)
- Testing
- Tamoxifen, Regorafenib
- Where
- 21 sites in France
- Volunteers
- 68 people
- Sponsor
- ARCAGY/ GINECO GROUP
Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates the effectiveness of palbociclib and binimetinib in treating patients with RAS-mutated cancers.
- Conditions
- Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8
- Trial name
- NCT05554367
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 265 sites in United States, Puerto Rico
- Volunteers
- 199 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 5132 in treating patients who have metastatic or…
- Trial name
- NCT00003892
- Testing
- ISIS 5132
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 22 people
- Sponsor
- NCIC Clinical Trials Group
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT01131234
- Testing
- Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)
Survivors Uniting for Remote Guided Exercise
The goal of this research study is to look at how live, online group exercise compares to recorded videos for helping increase physical activity levels, improve physical fitness and quality of life, and reduce loneliness among…
- Conditions
- Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior
- Trial name
- SURGE (NCT07290309)
- Testing
- Virtually Supervised Exercise Sessions, Asynchronous Group
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Colorado State University
Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis
Risk-Reducing Surgeries for Hereditary Ovarian Cancer
Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer"…
- Conditions
- Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy
- Trial name
- NCT03294343
- Testing
- salpingo-oophorectomy only by laparoscopy, salpingo-oophorectomy with hysterectomy by laparoscopy, Follow-up
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Lei Li
Ovarian Cancer
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed…
- Trial name
- ICON9 (NCT03278717)
- Testing
- Olaparib, Cediranib
- Where
- 54 sites in Australia, Canada and 2 more
- Volunteers
- 330 people
- Sponsor
- University College, London
Primary Ovarian Insufficiency, Infertility
Parental Project and Premature Ovarian Insufficiency
One of the main repercussions of POI is infertility. When the diagnosis of POI is announced, the question of fertility is addressed and the patient is often directed towards egg donation or adoption when she has a parental…
- Trial name
- ParentIOP (NCT05310617)
- Testing
- Survey
- Where
- France
- Volunteers
- 324 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovary Cyst, Fertility Issues
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI
GnRH antagonist protocol is currently a good strategy for controlled ovarian stimulation in women with PCOS undergoing IVF/ICSI cycles.
- Trial name
- NCT05751681
- Testing
- progestin primed ovarian stimulation protocol, dydrogesterone (Duphaston, Abbott), Cetrotide
- Where
- Egypt
- Volunteers
- 79 people
- Sponsor
- Zagazig University
Anovulation, FHA
FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity
Functional Hypothalamic Amenorrhea (FHA), the spontaneous cessation of the menstrual cycle for at least 6 months after menstrual cyclicity has been established, is a common and reversible form of anovulation not due to…
- Conditions
- Anovulation, FHA, Eumenorrhea, Polycystic Ovary Syndrome
- Trial name
- NCT00453219
- Testing
- Screening evaluation, Meal Response, Blood Collection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Ovarian Neoplasms
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resistant to platinum-based chemotherapy.
- Trial name
- NCT00038428
- Testing
- TLK286
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Telik
Ovarian Neoplasms
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC).
- Trial name
- NCT06964165
- Testing
- Niraparib, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Tesaro, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.